scholarly journals Intramuscular tumoral calcinosis near the arteriovenous fistula mimicking acute infection

2021 ◽  
Vol 104 (2) ◽  
pp. 003685042110185
Author(s):  
Qianjun Jin ◽  
Haiying Zhou ◽  
Hui Lu
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Calcium Phosphate ◽  
Arteriovenous Fistula ◽  
Acute Infection ◽  
Tumoral Calcinosis ◽  
Comprehensive Treatment ◽  
Left Forearm ◽  
History Of ◽  
Painful Mass

Tumoral calcinosis is a kind of tumorous calcified masses, which may progress in patients with chronic renal failure. Uremic tumoral calcinosis in the brachioradialis muscle presented like acute infection of the arteriovenous fistula has not been previously reported. A 49-year-old man came to our hospital with a 9-year history of hemodialysis and secondary hyperparathyroidism. He had a huge painful mass in the left forearm at admission. The treatment was debridement and cytoreductive surgery accompanied by parathyroidectomy and medical management of calcium phosphate imbalance. After the comprehensive treatment, the patient recovered from his previously affected forearm. This is an enlightening case of intramuscular tumoral calcinosis mass that presented mimicking the infection of the arteriovenous fistula. Nephrologists and surgeons should pay attention to early diagnosis and proper management of the primary disease to master the indication and opportunity of resection.

Calcium phosphate product level as a predictor for arteriovenous fistula re-operations in patients with chronic renal failure

Vascular ◽  
2018 ◽  
Vol 27 (3) ◽  
pp. 284-290 ◽  
Author(s):  
Mehmet Erin Tüysüz ◽  
Mehmet Dedemoğlu
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Calcium Phosphate ◽  
Arteriovenous Fistula ◽  
Product Level ◽  
Increased Risk ◽  
High Calcium ◽  
Phosphate Product ◽  
Group 2 ◽  
Group 1

Objectives There is an increased calcium phosphate product level causing the formation of calcification in the arterial wall and thus decreased quality of fistula in patients with chronic renal failure. The purpose of our study is to verify the relationship between arteriovenous fistula re-operation and high calcium phosphate product level. Methods Seventy-nine consecutive patients with chronic renal failure between April 2016 and February 2018 were included in the study. Patients having calcium phosphate product level ≥50 mg2/dl2 were defined as group 1, whereas those having <50 mg2/dl2 were defined as group 2. Primary outcome of interest was the need for re-operation during the follow-up and to determine the risk factors for re-operation. To determine independent predictors for re-operation, multivariate logistic regression model was used. Results The rates of redo and tredo operation were significantly higher in group 1 compared to group 2 ( p = 0.01 and 0.04). In multivariate analysis, phosphate (OR: 1.84, 95% CI: 1.00–3.40, p = 0.05) and triglyceride (OR: 1.01, 95% CI: 1.00–1.02, p = 0.04) levels for redo operation and calcium phosphate product level (OR: 1.11, 95% CI: 1.01–1.22, p = 0.03) for tredo operation were found to be independent predictors. Conclusions High calcium phosphate product level leads to increased risk of arteriovenous fistula re-operation by causing arterial stiffness in this patient group. Additionally, these re-operations place additional burden on morbidity and cost efficacy. Thus, we recommend keeping the calcium phosphate product level at the optimal level in these patients to avoid both the risk of arteriovenous fistula re-operation and the other cardiovascular problems.

scholarly journals Tumoral calcinosis, a diagnostic dilemma: a case report

2020 ◽  
Vol 7 (8) ◽  
pp. 1286
Author(s):  
Javed Altaf ◽  
Tajamul Rashid ◽  
Musharraf Husain ◽  
Mohammad Arif ◽  
Manzoor Ahmad
Keyword(s):  
Renal Failure ◽  
Case Report ◽  
Chronic Renal Failure ◽  
Soft Tissue ◽  
Medical Therapy ◽  
Surgical Intervention ◽  
Tumoral Calcinosis ◽  
Diagnostic Dilemma ◽  
Biochemical Assessment ◽  
Rare Diagnosis

Tumoral calcinosis is a rare diagnosis characterized by deposition of calcium salts in peri-articular soft tissue regions. It is divided into primary and secondary varieties. The primary tumoral calcinosis is further divided into two types; primary hyperphosphatemic type and primary normophosphatemic type. The secondary variety occurs in association with chronic renal failure. Biochemical assessment and typical radiographic features help in diagnosis. Mainstay of treatment for primary variety is surgical. Secondary variety is mainly treated by medical measures. Surgical intervention is reserved for patients who do not respond to medical therapy.

scholarly journals Familial Atypical Hemolytic Uremic Syndrome with Positive pS1191L (c.3572C> T) Mutation in CFH A Single-Center Experience

2019 ◽  
Author(s):  
Fadime ERSOY DURSUN ◽  
Gözde YESIL ◽  
Hasan DURSUN ◽  
Gülşah SASAK
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Family History ◽  
Hemolytic Uremic Syndrome ◽  
Atypical Hemolytic Uremic Syndrome ◽  
Gene Mutations ◽  
Factor H ◽  
The Other ◽  
History Of ◽  
Uremic Syndrome

Abstract Background: Atypical hemolytic uremic syndrome is a condition characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury, which can exhibit a poor prognosis. Gene mutations play a key role in this disease, which may be sporadic or familial. Methods: We studied, 13 people from the same family were investigated retrospectively for gene mutations of familial atypical hemolytic uremic syndrome after a patient presented to our emergency clinic with atypical hemolytic uremic syndrome and reported a family history of chronic renal failure. Results: The pS1191L mutation in the complement factor H gene was heterozygous in 6 people from the family of the patient with atypical hemolytic uremic syndrome. One of these people was our patient with acute renal failure and the other two are followed up by the Nephrology Clinic due to chronic renal failure. The other 3 persons showed no evidence of renal failure. The index case had a history of 6 sibling deaths; two of them died of chronic renal failure. Plasmapheresis and fresh frozen plasma treatment was given to our patient. When patient showed no response to this treatment, eculizumab therapy was started. Conclusions: The study demonstrated that a thorough family history should be taken in patients with atypical hemolytic uremic syndrome. These patients may have familial type of the disease and they should be screened genetically. Eculizumab should be the first choice in the treatment with plasmapheresis. It should be kept in mind that the use of eculizumab as prophylaxis in post-transplant therapy is extremely important for prevention of rejection.

scholarly journals Surgical repair of aneurysm of arteriovenous fistula in patients with chronic renal failure

2014 ◽  
Vol 1 ◽  
pp. 17-20 ◽  
Author(s):  
Faruk Cingoz ◽  
Celalettin Gunay ◽  
Adem Guler ◽  
Mehmet Ali Sahin ◽  
Bilgehan Savas Oz ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Arteriovenous Fistula ◽  
Surgical Repair

Tumoral calcinosis associated with hypercalcemia in a patient with chronic renal failure

2010 ◽  
Vol 15 (1) ◽  
pp. 154-158 ◽  
Author(s):  
Ryoko Horikoshi ◽  
Tetsu Akimoto ◽  
Daishi Meguro ◽  
Osamu Saito ◽  
Yasuhiro Ando ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Tumoral Calcinosis

Hepatic Metabolism of Aminopyrine in Patients with Chronic Renal Failure

1978 ◽  
Vol 54 (2) ◽  
pp. 133-140 ◽  
Author(s):  
S. Scherrer ◽  
B. Haldimann ◽  
A. Küpfer ◽  
F. Reubi ◽  
J. Bircher
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Renal Insufficiency ◽  
Serum Creatinine ◽  
Hepatic Metabolism ◽  
Normal Subjects ◽  
Hepatic Disease ◽  
Dialysis Treatment ◽  
History Of ◽  
Aminopyrine Demethylation

1. To evaluate potential alterations in hepatic metabolism of drugs occurring in patients with renal insufficiency the fate of aminopyrine was studied in 17 patients with chronic renal failure and in 27 normal subjects. 2. Although patients with chronic renal failure exhibited large variations, their aminopyrine plasma disappearance times (mean 0·62 ± sd 0·24 h−1) were significantly higher than those found in normal subjects (0·30 ± 0·07 h−1, P < 0·002). 3. 14CO2 derived from [dimethylamine-14C]aminopyrine disappeared from breath more rapidly in patients with chronic renal failure and a history of analgesic abuse (0·40 ± 0·04 h−1) than in control subjects (0·22 ± 0·03 h−1, P < 0·01) and in other patients with chronic renal failure (0·24 ± 0·04 h−1). 4. Dialysis treatment and serum creatinine concentrations were not correlated with the rates of aminopyrine metabolism. Two additional patients, however, with combined renal and hepatic disease, exhibited markedly slowed rates of aminopyrine demethylation. 5. Although chronic renal failure by itself might not alter microsomal drug metabolism it is concluded that, in patients with a history of abuse of phenacetin-containing analgesics, marked acceleration in aminopyrine N-demethylation may be observed.

scholarly journals The Study of Biochemical Markers in Chronic Renal Failure Patients in Pre- and Post-Haemodialysis

2021 ◽  
Vol 53 (03) ◽  
pp. 259-264
Author(s):  
Mohammed Abed Jawad ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Lipid Peroxidation ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Group Method ◽  
Control Group ◽  
Renal Markers ◽  
Patients With Diabetes ◽  
History Of ◽  
Notable Increase

Background: The current research is designed to investigate alterations in lipid peroxidation (malondialdehyde - MDA) and renal markers (urea and creatinine) in patients of chronic renal failure (CRF) as compared to the control group. Method: The study included 55 subjects, who were separated into two groups: control group, which included 15 healthy members with no history of systematic illness; and patients group, which included 40 patients with CRF divided into four groups “Non: CRF patients without any accompanied disease, DM: CRF patients with diabetes mellitus, HT: CRF patients with hypertension, and HT + DM: CRF patients with diabetes mellitus and hypertension”. Results: The findings reveal that there is a notable increase in serum concentration of MDA, urea, and creatinine, in patients group as compared to the control group. Conclusion: In all chronic renal failure patients with or without any accompanying disease, lipid peroxidation is present in pre- and post-haemodialysis patients as well as patients with CRF have high levels of urea and creatinine compared with healthy groups.

Sign in / Sign up

Export Citation Format

Share Document